Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas

By Vallette Sophie   Serri Karim   Rivera Juan   Santagata Patricia   Delorme Sophie   Garfield Natasha   Kahtani Nora   Beauregard Hugues   Aris-Jilwan Nahla   Houde Ghislaine   Serri Omar  

Pituitary, Vol. 12, Iss. 3, 2009-09 ,pp. : 153-157

Springer Publishing Company

Access to resources Recommend Favorite

Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment

By Shraga-Slutzky Ilana   Shimon Ilan   Weinshtein Ruth  

Pituitary, Vol. 9, Iss. 2, 2006-06 ,pp. : 151-154

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of Cabergoline in Long-Term Use: Results of Three Observational Studies in 1,500 Patients with Parkinson’s Disease

By  

European Neurology, Vol. 46, Iss. 1, 2001-12 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

Independent Regulation of the Cycle and Acceleration in Parkinsonian Gait Analyzed by a Long-Term Daily Monitoring System

By  

European Neurology, Vol. 69, Iss. 3, 2012-12 ,pp. : 134-141

Karger

Access to resources Recommend Favorite

Effect of Long-Term Homocysteine Reduction with B Vitamins on Arterial Wall Inflammation Assessed by Fluorodeoxyglucose Positron Emission Tomography: A Randomised Double-Blind, Placebo-Controlled Trial

By  

Cerebrovascular Diseases, Vol. 27, Iss. 3, 2009-02 ,pp. : 259-265

Karger

Access to resources Recommend Favorite